Physician profile
Eric A Pollack
NPI 1912966821
$15,418.13
in general payments reported to CMS, 2019-2025
40 companies · $3,646 in 2025
The $3,646 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,506 · 2020: $504 · 2021: $202 · 2022: $1,740 · 2023: $3,660 · 2024: $3,160 · 2025: $3,646.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $16.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,449.43 |
| Education | $16.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,932.00 | 2019-2025 | |
| Celgene Corporation | $1,406.79 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $1,290.62 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,081.89 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,014.57 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Scientific Affairs, LLC | $917.26 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $690.18 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $601.95 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $497.25 | 2019-2025 | Sucraid, Sucraid |
| Pfizer INC. | $460.92 | 2019-2025 | |
| Ardelyx, INC. | $436.32 | 2023-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $348.78 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $338.71 | 2023-2025 | Omvoh, Zepbound |
| Medtronic, INC. | $311.99 | 2022-2024 | Gi Genius |
| Boston Scientific Corporation | $229.29 | 2021-2024 | Resolution Clip |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $223.55 | 2024-2025 | Vegzelma, Zymfentra |
| Daiichi Sankyo INC. | $190.48 | 2019-2025 | Injectafer |
| Aimmune Therapeutics, INC. | $188.76 | 2024-2025 | Vowst, Zenpep |
| Madrigal Pharmaceuticals | $187.31 | 2024-2025 | Rezdiffra, Resmetirom |
| Ferring Pharmaceuticals INC. | $165.03 | 2019-2025 | Rebyota |
| Phathom Pharmaceuticals, INC. | $138.63 | 2024-2025 | Voquezna |
| Allergan, INC. | $108.86 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $104.27 | 2024-2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $91.56 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.65 | 2023 | Cyltezo |
| Merck Sharp & Dohme LLC | $47.20 | 2023-2024 | Dificid, Zinplava |
| Nestle Healthcare Nutrition INC. | $44.43 | 2023 | |
| Concordia Pharmaceuticals INC. | $43.12 | 2019 | |
| Ucb, INC. | $30.61 | 2019 | |
| Romark Laboratories, Lc | $30.00 | 2019 | |
| Novo Nordisk INC | $29.03 | 2025 | Wegovy |
| Sandoz INC. | $28.53 | 2023 | Hyrimoz |
| Organon LLC | $24.34 | 2025 | Hadlima, Renflexis |
| Ironwood Pharmaceuticals, INC | $22.19 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $21.17 | 2025 | Lesionhunter |
| Intra-Sana Laboratories | $20.80 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Alnylam Pharmaceuticals INC. | $17.71 | 2025 | Givlaari |
| Evoke Pharma, INC. | $16.96 | 2025 | |
| Endo Pharmaceuticals INC. | $14.70 | 2019 | |
| Braintree Laboratories, INC. | $12.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.